Showing results (341-350 of 587) with videos related to

Sort By:
Pageof 59
BMJ Open|December 26, 2022
Epidemiological Study to Assess the Prevalence of Lung Cancer in patients with smoking-associated atherosclerotic cardiovascular diseases: PREVALUNG study protocolDavid Boulate, Marine Fidelle, Caroline Caramella, et al.
Clinical Lung Cancer|June 12, 2017
A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung CancerBonnie Glisson, Benjamin Besse, Manuel Cobo Dols, et al.
Annals of the Rheumatic Diseases|June 11, 2017
Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatmentRakiba Belkhir, Sébastien Le Burel, Laetitia Dunogeant, et al.
Cancer Treatment Reviews|July 20, 2025
De-escalation strategies with targeted therapies in non-small cell lung cancerMartina Bortolot, Jordi Remon, Paolo Bironzo, et al.
Pathology, Research and Practice|November 5, 2015
Glut-1 intensity and pattern of expression in thymic epithelial tumors are predictive of WHO subtypesVincent Thomas de Montpréville, Pauline Quilhot, Lara Chalabreysse, et al.
Lung Cancer (Amsterdam, Netherlands)|August 10, 2018
Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancerByoung Chul Cho, Grace K Dy, Ramaswamy Govindan, et al.
Virchows Archiv : an International Journal of Pathology|April 15, 2021
Tumor mutation burden testing: a survey of the International Quality Network for Pathology (IQN Path)Francesca Fenizia, Nicola Wolstenholme, Jennifer A Fairley, et al.
British Journal of Clinical Pharmacology|December 1, 2022
Population pharmacokinetic modelling of tremelimumab in patients with advanced solid tumours and the impact of disease status on time-varying clearanceMichael Hwang, Yen Lin Chia, Yanan Zheng, et al.
Cell Cycle (Georgetown, Tex.)|January 25, 2013
Prognostic value of LIPC in non-small cell lung carcinomaLorenzo Galluzzi, Aicha Goubar, Ken André Olaussen, et al.
Journal for Immunotherapy of Cancer|May 26, 2022
Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodiesMathieu Larroquette, Jean-Philippe Guegan, Benjamin Besse, et al.
Pageof 59